Aldeyra Therapeutics (ALDX) said in a regulatory filing Wednesday that Chief Development Officer Stephen G. Machatha notified the company of his intent to resign to pursue other opportunities, effective around March 31.
Machatha's resignation did not stem from any disagreement with Aldeyra, the company said in its 8-K filing with the US Securities and Exchange Commission.